Yamin ‘Mo’ Khan
CEO at HVIVO PLC
Replay available
Interim results for the six months ended 30 June 2026 hosted by hVIVO (LSE:HVO) on Investor Meet Company. Replay available.

On 6ix: 6ix.com/event/hvivo-plc-hvo-interim-results-for-the-six-months-ended-30-june-2026
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good afternoon, ladies and gentlemen, and welcome to the HVIVO Interim Results Investor Presentation. Throughout today's recorded meeting, attendees will be in listen only mode. Questions are encouraged. They can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your question at any time and press send. Before we begin, we'd like to submit the following poll. If you give that your kind attention, I'm sure the company will be most grateful. I'd like to hand over to the management team today. Mo, good afternoon. Thank you, Mark. Good afternoon. Good evening, everyone. Welcome to HVIVO's interim results covering the period of first half of twenty twenty six. This is the obligatory disclaimer we have for obviously, it's the complete under AIM.
0:41 I'm Yamin Mo Khan. I'm the CEO of HVIVO. I've been here for about four and a half years. On my right here is Steven Pickerton, who's our CFO and has been the CFO for over four years. And on my left, we have our friend Andrew Cashbold, who's our chief scientific officer. And he's been with the company for over twenty years and has really been the the brains behind the development of our challenge models that we see in action these days.
1:13 So we'll come straight onto the interim results. So for those of you who maybe don't know about the company, we are a full service early stage clinical development provider providing nonclinical and clinical services to both the biotech and pharma industry. We have locations across Europe, in in France, Germany, Netherlands, and also The UK. We have clinical trial units in in London, both in Whitechapel and in Canary Wharf, and three units in Germany in Kiel, Mannheim, and the recently acquired unit in Berlin. In The Netherlands, in both Breda and in Leiden, we have a consulting arm and then our biometric, which is data management and biostat obviously in Paris. So as you can see, we have grown significantly both with regards to the number of staff we have and and also the number of countries we cover across Europe.
2:14 Late last year, we reorganized the company into four distinct service lines. So the first line is the consulting arm where we help customers design new clinical trials, provide them consulting services to meet with regulatory bodies across different countries, and also look at the what's called the preclinical data, the the CMC and the drug formulation, the PK, and so on. Secondly, we have the the clinical trial unit. This is where where we typically conduct all our nonhuman channel trials. So the phase phase one and the phase two clinical trial as well as phase three site services. And then, of course, the original human challenge trial, so the sub sign still continues to exist and grow.
3:03 We we also have a a laboratory standalone service line. So we not only do labs cater for the the clinical trial and the human child trial, but now on on their own, on their own merit, we can outsource this as a standalone service to customers. So the reason why we have done this is that we want to be able to provide end to end service to our customers. The way I look at this is we have four distinct vertical, but we have one horizontal in the sense that we can take a client through from preclinical, so this is before even the drug has gone into humans, all the way to a score proof of concept of phase two where you expect to see a signal of effectiveness for the drug in a human body. This also means that our addressable addressable market has increased, and we're able to talk to our customers independent of what stage they're at during the drug development. Whereas, historically, we typically spoke to them around the phase two stage, which is the human challenge for our phase.
4:03 Now whether they're in nonclinical, preclinical, or across the different phases of clinical development, we have a service that we can sell. So that that basically means that, effectively, every drug developer is a potential client of ours.
4:23 Now coming on to our h one twenty twenty six results. Steven will provide a little bit more color, but we've already provided a fairly detailed trading update in July of this year, and we're basically mostly reinstating the numbers we provided then in the in the first half of twenty twenty six. So £16,300,000 of revenue. We we said low single digit EBITDA loss and then a £13,000,000 in cash at the end of June. We've now given guidance towards
4:58 the full year 2026, and we're stating around £47,000,000. So this is slightly lower than what's currently in the consensus, and this is mainly due due due to deferment and not cancellations. So we were expecting our our con contracts to continue to execute. But, unfortunately, for a number of reasons, a couple of contracts have been delayed and pushed into 2027 and 2028. But we have seen significant growth across our our new sales and new fund tracks, including in human challenge trials. We signed three different human challenge trials, and we will provide more details on that. And this has helped by the fact that a 45% year on year increase in new proposals, 26% increase in the value of the proposed proposals, good conversion rates, building up the order book to £65,000,000 underlying, and then with the addition of the acquisition in Berlin, taking this up to 72,000,000.
5:58 So that really gives us excellent visibility for the rest of this year and good visibility into 2027. This is the highest the order book has been in the history of the company, so I feel very confident that we are on the up. We believe strongly that the first half of twenty twenty six is the trough, and we'll see almost doubling of the revenue from the first half to the second half. And we expect a year to year growth from '26 to to '27 that we are turning as significant. So thanks, mate. And just talking about the h one performance versus last year 2025, h one performance '24 versus 16,300,000.
6:44 And you can see the huge difference here is the decline in the HCT revenues year on year. And if you remember in 2025, we did have a high level of cancellations, and that's part of it. Also, the current h one twenty twenty six, we did expect some higher HET revenue, but that has been pushed out, as Moe just mentioned, to '27 and 2028 as well as into the second half of twenty twenty six. The clinical services has increased, but actually year on year rates on a like for like basis. It's flat aligned. The it is just because it is it's an additional million. It relates to the it's a full year impact of acquisitions that we made in January 2025.
7:34 Labs is a good solid increase. It's growing a 110%. It's also slightly low a lower base, but it has got a lot of potential. We have invested heavily in our lab space in London, and we're beginning to get traction there. And that's good to see, and that is building up nicely. Consultancy, part of the delays that we have faced in clinical services and HCT has also impacted the consultancy work as well.
8:04 So going on to, what we look at for the rest of the year, you can see the second half of the year, we're looking at delivering 31,000,000, and it's almost double what we delivered in h one twenty twenty six. This is what we guided. We did guide that we would be h two weighted. 31,000,000 includes 3,000,000 from the acquisition that we made beginning of the year, at least in in August. So it is backed by a strong order book, and it's a strong performance. And, therefore, we're guiding now 47,000,000 for the rest of the year for for the full year. It does go back to the fact that we have had I think one of the things I take away is that when we set the guidance of about fifty fifty one million for the core business, all those contracts that we expected because we started from a very low order book basis of 30,000,000 has materialized.
9:02 What we haven't really understood was that some of these things would delay more than we expected cause we always hedge those bets, but some of that is out of our control, and that's why it's pushed on. But that bodes well for 2027.
9:21 So lower revenue means lower outputs and EBITDA, so we made an EBITDA loss of 4.5. This is a sort of an analysis between what the profit that we made in the first half of H1 last year. It's the HET revenue. And if you remember in 2025, we had a lot of cancellations. That cancellations didn't have any very variable spend attached to it, so it flows through straight through. As well as we also spent in 2025, we were doing some building some new models, which are completed in 2025. And as we're not no longer doing that, you know, the difference in revenue, you know, from 16 to 24,000,000 has sort of dropped through to the bottom line from an operational point of view.
10:09 Then full year impact of the acquisitions and overheads is obviously added to our cost base of $500,000 but we have also made some savings during the year on a year on year basis. We do maintain a very tight control of our costs. So obviously, with that higher revenue in the second half of the year of 31,000,000, we do expect to be we are forecasting to be EBITDA positive. So we will reduce that loss to a low single digit loss for the for the full year. So this cash flow does this is a walk forward from the beginning of the year, dollars 14,300,000 and $13,000,000 at the half year. Obviously, cash from operations is going to be negative because we made a loss of 4,500,000 in EBITDA. But what's interesting to see is the 4,500,000 net working capital movement is positive, and that is is a turnaround. In the last three reporting periods that we've done, what I have been presenting at, we have had net working capital negative.
11:18 So that is positive, and that's why the cash has held up nicely from 14.3 to 13,000,000. Some of that will reduce in the second half, that 14.5 will reduce, and that's because it is driven by some of the ACT trials that we have signed up, the three that we've signed up this year, and some of that gets starts getting delivered in the second half of the year. And so it will reduce, and so cash will end up lower at the end of December by by about, you know, down to about 8 or 9,000,000. So we do expect cash to reduce, but that's also because at the end in the second half of the year, we do have a lot of field study work, and so it will impact our debtors because CROs take a long time to pay you on delivery. It can be up anything up to ninety days, and we do have a high volume of work that we'll be delivering in October, November, and December. So cash will be lower by the end of December, but, you know, with the strength of the order book going forward, cash is looking reasonably good in place. The other thing to note is that the acquisition we've made will have no impact on our cash position to date.
12:33 Investments, we haven't had too many much investments in the business. We're already fully quite well invested. There is maintenance investment that happens, but it's not very significant at this stage. Next slide. Tools. So, I mean, this is my favorite slide of the whole presentation because it's the most important parameter looking forward when you project what's gonna happen with this company for the next six, twelve, eighteen months. So so you can see the way the order book has progressed since 2023 and how we've seen that slow decline due to market conditions, drop in activities, and so on. But we saw increase in proposals, especially from towards the end of last year into the first half of this year and second half of this year, and some of those have now been contracted.
13:28 So remember, we changed the algorithm of how we determine our order book. So we wanna be more conservative and and try and reduce the translation rates that we saw previously in in 2025. So as a result, the underlying order book at the end of June this year is still at £65,000,000. And with the addition of the acquisition of Berlin, it's increased to £72,000,000. So this gives us excellent visibility, as I said, for this year, but also for 2027. In fact, some of this order book goes straight into 2028. Now this is on top of additional awards we've had that not have been fully contracted. So this is the main reason why I feel confident about 2027 and what we can do and why we are forecasting a significant growth from '26 to '27.
14:28 And with all of this, human challenge drives remain our core business, but we are not just solely relying on human challenge trials anymore. So you can see the the the dark green segment of this pie, this doughnut, if you will, and how that's
14:45 decreasing. And that's partly due to inorganic addition of new clinical trial services as well as organic growth in the clinical trial business as well as the lab business, especially. And I think this to me is key that we're no no longer a niche provider in human child trial. We're a much more diversified, resilient provider of clinical and drug development services. But as I mentioned, human challenge trial is still a key differentiator for us. This also means that the addressable market for us has significantly increased. We are now able to run clinical trials in a number of therapeutic areas and not just be focused on infectious diseases. It also means that we have a greater number of customers providing us with revenues. So we're not relying on one or two top clients and also means that we get more revenue per client because we are engaging with our customers at much earlier stage and continuing with them through the life cycle of product development. A key example of this was Sadara with whom we ran a human challenge trial and then a phase two field trial, a phase three trial, and the body services. So in fact, when you look at the the metrics, only of a third of the total revenue we recognize with with the program came from human challenge for us. The rest were the non challenge for our related revenue. And I think that to me really speaks volumes when we think about growing the company forward
16:16 and how we can maximize revenue per client. As Moe mentioned, human challenge trials are still a really important part of our business, and we still are attracting customers to do that type of work with us. And that's mainly because they do get their data so much faster. So from the moment they contract with us in that clinical trial agreement, they can get their data within twelve months, which is about three and a half times faster than if they did it with the natural infection studies. And, of course, time to market is really important for these products, so that is absolutely everything for them. And what we've seen in 2026 is there has been a a sub shift of the type of studies that we're getting. So you're probably you're probably aware of some sort of of, anti vaccine movements in some parts of the world. What we're seeing in 2026 is an actual shift towards slightly more antiviral studies coming towards us now than the vaccine studies.
17:12 This is slightly cool. This does go does go in different ways, but it's really positive at the moment that we are seeing antivirals getting good funding. And these people are coming to us to do these studies because we are the world leader in doing human channel studies. And that really comes from our extensive experience in doing it and, of course, the very important infrastructure you need to be able to deliver that. So, of course, that's our 50 bed unit, very vital delivering that. Our dedicated recruitment team and the flu cam database, all of those combined are really vital to be able to deliver these challenge studies. And not only that, they also act as a barrier to entry for others and the competition in this area. So because we're infectious disease experts, we're able to offer these studies and actually design them as well. And that's really where challenge studies underpin the whole of this business because they do interact with all the other three pillars of the business. So when the contract comes in, unlike a traditional clinical trial where their sponsors come in, give you the protocol to run, with the challenge studies, it's very specialized. You need the infectious disease and the challenge model expertise to get and design those studies. So we design studies for our clients. And we use the consultancy group to do that and to use the medical writing to build around it. And laboratories, of course, are analyzing the samples and doing the screening for the trials. Our recruitment team coming from the clinical trials site and, of course, the 50 bed unit to actually deliver these. So it truly is an integrated platform.
18:39 And on the next slide, can go and talk to you about the actual contract wins that we've had recently. So you probably would have seen the phase three pivotal trial in bordetella pertussis, that's whooping cough. This is a really big moment. This is a challenge that is being used for efficacy for a phase three trial. It's one of the first times that's been done. So this is a really big, important study, not just for HVIVO, but actually for the scientific community. In addition to that, we've also signed two influenza trials, one's for monoclonal antibody tests for flu prevention and also prophylactic flu prevention, again, for the trials clients. So we are seeing a very strong order book and growth back returning into the challenge business. And as we mentioned, really is creating good opportunities. And as as we are now talking to our clients earlier, now we're able to
19:26 offer phase one studies. We're able to do phase one combined with human channel studies, so we get that earlier engagement. And the earlier engagement means we can then have a greater platform to sell. So, for example, we've got got clients coming in also for the laboratory work preclinically, and then we can extend to do laboratory work for the channel studies, and then that extends on to support them into phase two, phase three studies. We were not able to do that until we moved into our new facility two years ago because we've reached capacity in the labs. The labs have now got much more capacity and able to support our clients moving forward. So that really does drive pipelines, not just in challenge trials, but of course, in the lab business as well. In addition to the traditional infectious disease market for challenge studies, we're actually seeing this branch out into new types of areas as well. So COPD and asthma challenge studies, we're still using viral pathogens, but instead of being conducted in healthy individuals, it's being conducted in asthma and COPD challenge. So we are seeing some emerging new opportunities into this space.
20:28 On the right hand side is a really important graph actually because it's a nuance about how these contracts are run. Our customers understand that doing channel studies are unique, and they need to reserve their space in this very specialized unit. Because of that, on the point of contract signature, there is a milestone payment. Hence, we're cash positive right from the very point of contract signature. That's a dark line on the graph on the right hand side, and the green line is the revenue. And then once we start to actually recruit the volunteers, our clients also understand that these challenge studies need a big recruitment engine to screen lots of people because we need to screen people to make sure they don't have too high antibodies against the pathogen so they will get sick. That's different from any other type of trial.
21:13 So because of that very large screening, we need to have an influx of a milestone at that point. So, again, that's the next inflection you really see as a milestone payment upfront to cover those screening costs. And this is why for the large majority of the life cycle of a channel study, actually, they're cash positive throughout.
21:34 So what we are seeing, you know, just to really summarize the channel study, we are seeing this core differentiator driving our growth still and creating new opportunities. So we're actually really pleased with how this has picked back up. Thank you, Andrew. So I just wanna refer us back to some of the strategic growth priorities we set ourselves early this year and what progress we have made on those. So first one is cardiometabolic. So as you know, our Mannheim colleagues, the clinical product unit based there is is led by a key opinion leader endocrinologist. So he's an expert in diabetes, obesity, or what we call the cardiometabolic therapeutic area. And I think we've been able to capture significant amount of business related to obesity and diabetes.
22:23 I'm sure all of you are aware the big boom in obesity clinical research, clinical development, and all that entails. So as a result, we've been able to recruit patients using a flucon equivalent that we launched in in Germany late last year. On top of that, we've been able to create some real good relationship with mid sized pharma as well as providing clinical trial services to a lot of big pharma that I'm sure you know the names of who are working in obesity and diabetes. So we made significant progress in that and done quite a few deals in the obesity area. On respiratory, of course, we've got inherent experience in respiratory considering all of the human child trials we have run to date, at least, have been in what we call respiratory diseases. The fact that they are infectious diseases, but they impact the respiratory system. So we already have in house experts in dealing with respiratory diseases, and we've utilized that to basically prepare ourselves to run nonhuman channel trials in respiratory diseases such as CRO sorry, COPD, and also asthma. Now this market really, we're targeting not only pharma biotech, but also other CROs whom we're helping to recruit patients into large scale clinical trials. We've also got an ongoing prescreening clinical trial, which we use to supplement our our database, and we have already been awarded several projects in these areas.
23:54 The third piece for this is laboratory. So as I mentioned already, we started as a company as a as a a laboratory service provider. So and then we evolved into the laboratory being the support of for human child trials. And since the move to Grain Wolf, we now have the capability and the capacity to run standalone laboratory project. And that's what we've been able to do. So not only do this for the human challenge trials we run, but also we've been able to do standalone project. And one of the key advantages of this is that we're able to create a relationship with the customer at an early stage. So we now have a case where we have a a client with whom we are providing very early departing services and now moving into potentially a human challenge for us. So that that's a really kind of the key model for us when we look at the end to end unified platform. In addition, we've last year, we invested in some new capabilities with regards to next gen sequencing and and d v PCR, and those have already producing excellent revenues as as they go forward. So this is another area that we are developing. We're hoping to continue to increase the order book, and, also, we you'll see higher higher revenue coming from the laboratory service line.
25:13 So when you look at the broader market, what we now see is that there is more funding for the biotechs. There is more m and a activity within the biopharma industry, and people are making decisions. So I know I've spoken to you over the last twelve, eighteen months and always stated that we have this huge sales pipeline. But the and I've also said this, the key risk with that has been that that sales pipeline has not always been converted into what we call as contracted work or contracted order book. But now we're seeing that decision making. So as I mentioned, we we have a current 72,000,000 order book. First half last year, was 27. End of twenty five, was 30. And now it's the 70. So clients are making such are signing contract and progressing.
26:03 Admittedly, a couple of projects have been deferred, which have impacted 2026, but then are lost or canceled, and we hope to progress them in '27 as well as going into 2028. We also know that biotechs are doing more and more clinical research because the the big pharma with what we call this huge patent cliff they're approaching in the next five years will need to supplement their pipeline with new m and a activity buying new biotech assets. So the biotechs are busy developing these drugs, and we, as a one stop shop for small companies, are best suited in helping these customers to go from preclinical to just about getting into humans to proof of concept, which is a a value inflection point, and they can demand big money from big pharma.
26:51 In addition to this, when it comes to infectious disease, we've now also seen more interest in Eli Lilly, for example, acquired three vaccine companies in a week. So that shows that Eli Lilly, who have really deep pockets, are also interested in the ID space. And, obviously, of course, I've already mentioned, there continues to be huge interest in in drug development in that area.
27:17 We acquired Berlin, CS Berlin, in August of of this year. And, you know, if you ask me why do we do this, and there's kind of a number of reasons. Of course, the numbers were very attractive, so the financial terms, which Steve will talk about, were very, very good to us, we felt. The fact that it's able to expand into new areas of dermatology and women's app was key. The other key item for us was that we are able to cross sell to these customers. So, remember, the platform we have for clinical trial is exactly the same. So the the facilities, the the resources, the processes, the system that we utilize, whether we run clinical trials in infectious disease or respiratory or cardiometabolic or woman's health or dermatology are exactly the same. So without addition of huge CapEx or anything, we're still able to service these different types of therapeutic areas with with
28:13 with the same platform. The only difference is the fact that we may have one or two key opinion leaders who can show disease expertise when they're designing and executing these clinical trials. So this also means that we have access to a much larger country in Berlin being a very major city. It has over 6,000,000 potential patient population, so recruitment for new clinical trials makes this much easier. It also increases the capacity to over 200 beds and gives us the option to run multi site large clinical trials. So all under one umbrella. Remember, our key differentiator compared to most of the CRO is the human challenge trial, but the second one is that we own our clinical sites. So there are not many CROs out there who own multiple sites where they can run their own clinical trials, and that that's a key thing for us. Dermatology and women's health are both good growing disease areas, and we expect to see increased interest in both of these. Dermatology also falls under the immunologist, so indications like atopic dermatitis are on the up, and a lot more drugs are being studied in there.
29:19 Women's health is generally underserved when it comes to drug development, and we expect to see increases in this area going forward. So all of this effectively makes us a leading European provider in early clinical development.
29:36 So some of the highlights on the acquisition costs. So we paid €25,000 just to get the deal over the line. Obviously, it's a it's a minimal effect on on on our cash flow. The earn out of the deal is about is 18% of each revenue across '26, '27 and '28, the annual revenue achieved in those in those years across those three years. The effective rate is slightly less because of the 18% only applies to certain revenues and other revenues is slightly less than that. So in essence, we're expecting a sort of an earn out of roughly €6,000,000. And if we deduct the pension liability that we're taking on, then the net impact that we've been paying out in cash terms is 4,000,000.
30:27 And it is self funding. Business is profitable. It's generating well, it's it's generating good revenue. It is profitable. It's generating cash, and that cash will be more than sufficient to pay the earn outs. The other thing to understand is that the earn out is scalable. It scales up and down, and there's a minimum level of revenue that has to be achieved before the earn out starts clicking in.
30:57 So effectively, you're getting you're paying about 58 p in the pound for every pound of revenue, which we think is a a really good deal less the pension liability. The impact on this year's results, it will get 3,000,000, and this is the incremental revenue to the group. So it's they actually if you look at their revenue, you know, we we guided in the RNS was €10,000,000, but 18% of that revenue is already work that we that is outsourced to HVIVO, the other companies of HVIVO and other services HVIVO provide to deliver that to deliver that revenue. So that that 3,000,000 is net of, I mean, sort of of work that we provide from our other companies to deliver that figures. We are very ingrained with Sierra's Berlin.
31:54 EBITDA contribution will be no point 5,000,000. It's they are having a strong h two as well. They did have a slow start in the year, but the full year is looking good. And, certainly in the formats that we own them own them, they will deliver a contribution margin of 500,000. Contracted order book is really solid, and I think what I I really like about it is that it's on the top end. So if you think about clinical services, because of the short time scale on getting new contracts on board, generally, at the beginning of the year, you're looking to be about 50% or 60%
32:38 contracted. And these guys are just over 60% contracted of the next twelve months of revenue that we're forecasting for them. So it is a good order book, and then they do have a good pipeline backing it up. So I think that's an it's give you a sort of flavor. You know, in summary, it's earnings accretive. It's self funding, and it's backed up by a very good order book. So it's a good deal.
33:06 Thank you, Steven. So just to sum up and appreciate with the headwinds we've had in 2026, we we are showing a guidance of £47,000,000. But you also have to remember the the quarter book coming from '25 and '26 was was £30,000,000. So we've done a lot of work to build that order book up, but, unfortunately, it was too late for the first half. The second half, the revenue is almost doubling, but even then, couple of projects have been deferred impacting the full year 2026. But as I said, that revenue go goes into '27 and '28. But you can see that that staggered growth. Right? So you see increase in proposals, you see increase in order book, and then you see increase in revenue. And that's the the logical sequence we we expect to see how this company will grow. The CRS Berlin position, I think, is a pretty good deal. Almost everyone agrees with that. That have been a strong commercial momentum across the different service line continues, especially for HCTs and and laboratory field.
34:16 We've got in 2027. I think I said we were going in with a at least the first half record order book, and we're forecasting significant year on year growth, and we're also forecasting positive EBITDA for 2027. We will integrate CS Berlin as it comes up. We're we're also widen our addressable market for the whole company. The general industry dynamics seems to be improving, as I mentioned, biotech funding is is boosting up, and the big pharma are busy doing a lot more m and a. And we had a capital market state in July of this year where we had key venture capitalists, biotech CEOs, and also big pharma presence who presented some of the key advantages of the service that we're offering and why it's a good fit for for the biotech industry.
35:11 So thank you very much for your time, and I look forward to the questions. That's great, Moe. Stephen, thank you very much indeed, guys, for updating investors. Please do continue to submit your questions just using the Q and A tab situated on the right hand corner of the screen. Just while the team take a few moments to review the questions submitted already, I'd just like to remind you, recording this presentation along with a copy of the slides and the published Q and A can be accessed via your Investor Meet company platform. Moe, as you can see, as usual, a number of questions from investors. Thank you to everybody once again for engagement on the call this afternoon. If I may just hand back to you, if I could ask you please to read out the questions where it's appropriate to do so, and I'll pick up from you at the end. Great. Thank you, Mark. So, yes, I'll go through as many questions as I can within the the time allotted. So the first question really is when can we expect to see a pickup in winning a CT contracts again?
36:04 Without these, share price will never really recover from previous highs. So I believe we are already seeing that. Right? So we've we've illustrated we signed our largest ever human challenge trial contract with Gilead, and then we've also signed two additional human challenge trials in the meantime. But maybe, Andrew, you can talk about what types of drugs are of particular interest to our customers now. Yeah. We are seeing an an upscaling in all of the challenge study contracts, actually, so which is great. So we are seeing certainly more antivirals coming through. So the the amount of money that's that was going into infectious disease is is still the same as it was previously. It's just instead of being split between vaccines and antivirals, we're seeing more of it going towards antivirals, although there are still some vaccines coming through for testing as well.
36:55 So although the type of products that are shifting to the antiviral market still, that's that's a good sign because we're seeing these new products being developed. We're also seeing some some antivirals, not just for treatments, which is traditional use of antiviral. We're actually seeing a pickup in business where from proposals of of customers who are designing antivirals as a preventative for diseases, so alternative to vaccines. These are will be targeted against people, for example, who might have, immune deficiencies where they wouldn't respond to a vaccine, for example. Right. Thank you. The next question is how will the company be affected by AI? So drug development in general, I don't think will be severely impacted by AI considering we still need to test a a molecule in a in a human body.
37:47 I don't know what's gonna happen in five or ten or fifteen years time. But for now and at least there's no replacement in obtaining data from doing clinical testing in human beings. We are using AI in the sense of some of the process we have across the different departments. So that's already in place. But if the question is, will AI basically stop all types of drug development? I can't see that for the foreseeable future. I think it would actually increase drug development because the AI will enable data to be analyzed across multiple different pathways, which humans couldn't do. And, actually, what I think we'll see is new classes of drugs coming out of discoveries made by using AI in the r and d platform. So I think it's actually very positive for new classes of drugs to come through, and it'll never replace the need to be able to do, human clinical trials. So, actually, I think this could be a very good upside for us in in the future years. Great.
38:48 You changed the order book methodology to make revenue visibility clearer and more reliable. So, yes, so we we changed our kind of algorithm to not report on order book for what we call startup agreements, but instead on clinical trial agreements to reduce the the risk of cancellations. So, historically, we we've seen cancellation from SUVs, but minimal cancellations coming from post clinical product product unit. As recently at July, you were still going for a high single digit revenue growth in 2026. Now less than two months later, revenue guidance has been cut, and you expect a full year EBITDA loss. What has gone wrong? You wanna take that? Essentially, it's comes down to two well, as we've already discussed, it comes down to lay delays. The HCT contracts have delayed. They're delayed in '27 to '28.
39:46 That has had an impact. Obviously, in h one, you've seen the impact, but it's also having an impact on h two to some extent. The other thing is that we do have high volume in h two. Not all of it is HTT. Only a small smaller portion of it is HTT. The mix of revenue in the second half of the year has a margin is somewhat lower, and so therefore, we're not getting quite profit to swing that around. But I I do think this is the beginning of a change, and it is evidenced by the order book. If you looked at the trend of the order book and and the revenue that's been recognized and following in the at the beginning of the if you look at the trend of the order book at the beginning of each year and the revenue that's delivered in the in the following year, you're getting a sense of where we could go. So the order book is changing. That will have an impact on the performance of this business and a positive impact on the performance of this business.
40:46 Thank you. And and I've got a link to the same question really is why should investors trust the order book in 2027 guidance if contracted work can keep up being can keep being pushed back? So we feel much more confident now because a lot of the contracts are near time to start an execution, so that that helps. Secondly, as I mentioned earlier, the the the kind of the the pre step to having a contract signed in what we call the awarded bucket. So this is the contract that have been work that has been awarded to us, but not yet contracted. So, typically, it takes three to six, nine months to get that into the order book. That's a significant amount. So we we feel that together with the existing order book and the visibility that gives us into 2027, And, also, in addition, there's awarded part of Upwork that will hopefully go into contract in the next six, nine months. That is amazing visibility for 2027, and that's why we are we are confident about 2027.
41:55 Because Steven, this is for you. You expect positive adjusted EBITDA in H2. Can you give us some indication of the EBITDA margin you expect to achieve in H2? And should we regard this as the beginning of a sustained return towards the group's historical margin levels? On first part, we talked about, yes, we made we made a 4,500,000 loss for h one, and then our guidance is a low single digit loss in EBITDA for the full year. So that's anywhere between 2 and 2 and 3,000,000. So therefore, the the profit for h two is roughly 2 to 3,000,000.
42:44 So that's where we that know, that's affecting from deductions on the guidance that we're giving, and it's more or less in that realm. The in terms of margins going forward, I do expect margins to improve and come back and be positive and going forward. It is very dependent on the mix of revenue. HET is you know, it has the highest margin. It has great margin in this business. It is not yet fully back in our numbers in terms of revenue terms. The order book has got some good HET stuff in it, and that will play out in 2027. But it's not playing out so much or to a large extent in h two twenty twenty six.
43:30 And I think the other thing to highlight is that although we have know, you we always talk about Iliad as a a big ACT contract, it's not going to be quite as profitable as a a normal ACT because that that pro that project that Iliad project is an outpatient project, so it's a bit more clinical service oriented. Clinical services margin is much lower. And if I'm looking at an EBITDA sort of business on clinical services such as Berlin, I'm expecting 10 to 12% margin going forward. Hopefully, with our scale and the investment that we make on IT and our recruitment plans, we can actually improve on that and get it between 1520%. But that's aspirational, and that will take a bit of time in the in the in the sort of medium to short term.
44:20 So normalizing, it's going to improve. As to whether it's normalizing, it really depends on the revenue mix, and I can't give a figure just yet. Great. I think you answered the next question already, to be honest. So the one after that, diversification, as this increases, will your GNA increase too? Not not significantly. We had this year invested in BD. We've expanded our BD reach and our team and our resources and the effort around it and the marketing as well. And we're expecting that to pay off. I don't think we've seen the full benefit. We should be seeing some benefit. We're getting a lot more traction on some of our deals and and our contacts. So, yes, there will be an increase in g and a next on on next year, year on year, but it will be sort of mid to, you know, mid mid mid single digit percentages.
45:17 So it's not gonna be a significant increase. What is the expected EBITDA margin and cash contribution from CIS Berlin? And when should shareholders expect the acquisition to become meaningfully earnings accretive? Berlin is already EBITDA accretive. It will make a profit of roughly it's expected to make a profit of about 500,000 in the in the four months that we own it. So it is already accretive. I expected it to be accretive. Henceforth, it has a strong order book. It has a great strategic value in terms of women's health and dermatology.
46:08 These are great indications that we are exploring and working on. So it will be accretive going forward, and it's immediately accretive. Okay. There's quite a few more questions. One key one here, I guess, what structural changes are you making so that a small number of delayed HCTs can no longer swing the whole group from profit to loss? So that's a really good question. So, historically, you know, we have been pure human channel trial players. So now that we have the diversified business, I think it does dilute the human channel trial change impact. And I saw you the the pie chart which shows that, know, less than 50% of twenty twenty two and six revenue will come from human challenge trials.
46:56 So as we continue to grow and build on all the different service lines, we we we expect to dilute the impact of human challenge trials per se. Because the bigger the revenue you have, the less impact one change in a in a HCT will have. So, hopefully, that that answer your question. The next one, what are 2027 revenue estimates and what percentage of that is already signed up? So I guess the the broker's consensus, if you will, because we haven't given guidance for next year yet, except saying significant growth growth. The brokers consensus around mid to high fifties, which will be a significant uptick. And, again, we've not given the percent visibility for next year, but it's higher than it's ever been at this stage of a year. So because of the order book we currently have, it shows really good visibility going into 2027.
47:58 You speak of work awarded, but not yet contracted. How much roughly is awarded, but not a contract? Appreciate there are no guarantees. Well, that's exactly why we we don't say it because there are no guarantees and, you know, this is the type of information that we we we now actually assess a lot more conservatively, and that's why we share what we say the fully contracted piece of work, which goes into our order book. So and that's the end of 72,000,000, which we believe is a is a very prominent and promising number. But I think that's all we we have time for. Thank you for your time today and and for your questions. That's great. Thank you to you all for updating investors. Ladies and gentlemen, if I please could ask you not to close this session as we now automatically redirect you for the opportunity to provide feedback in order the company can better understand your views and expectations.
48:47 It'll take a few moments complete, but I'm sure it'll be deeply valued by the company. On behalf of the management team of HVIVO, thank you for your
Follow hVIVO plc into a list and get an email when it puts out news.
CEO at HVIVO PLC
CFO at HVIVO PLC